Company Overview - BlissBio Inc. (百力司康) submitted its listing application to the Hong Kong Stock Exchange on June 29, 2023 [1] - The company, founded in 2017, is a clinical-stage biopharmaceutical firm focused on developing next-generation antibody-drug conjugates (ADCs) to address unmet needs in cancer treatment [3] - The core product, BB-1701, targets HER2 and is aimed at treating breast cancer, non-small cell lung cancer, and other HER2-expressing cancers [3] Financial Performance - For the fiscal years ending December 31, 2023, and 2024, the company reported revenues of approximately RMB 180.2 million and RMB 22.6 million, respectively [2] - The net losses for the same periods were approximately RMB 206.4 million and RMB 556.6 million, indicating an increase in losses [2] - The gross profit for 2023 was RMB 179.5 million, while for 2024, it was RMB 0.3 million [2] Revenue Sources - The company's revenue primarily comes from providing clinical trial materials and R&D services, as well as milestone payments from collaborations with external companies [4] - Revenue from the top five customers accounted for 100% and 99.9% of total revenue for 2023 and 2024, respectively [4] R&D and Competitive Landscape - The company has a strong ADC candidate pipeline supported by a proprietary technology platform that integrates various advanced techniques for precise ADC design [3] - The internal R&D team consists of 95 members, with about 50% holding PhDs or master's degrees, and an average industry experience of over 10 years [7] - R&D costs for 2023 and 2024 were approximately RMB 144 million and RMB 120 million, respectively, with the core product BB-1701 accounting for 59.3% and 45% of total R&D costs in those years [7] Industry Competition - The ADC industry is characterized by intense competition, with numerous multinational companies and leading biotech firms developing similar ADC drugs [6] - Competitors may have more substantial financial, technical, and resource advantages, potentially allowing them to advance their candidates more rapidly [6] - The company faces procurement concentration risks, with purchases from the top five suppliers accounting for 56.5% and 41.3% of total procurement in 2023 and 2024, respectively [6]

Core Viewpoint - BlissBio Inc. is facing increased uncertainty regarding the global development prospects of its core drug BB-1701 after terminating its collaboration with Eisai, which was previously expected to yield up to $20 billion in potential revenue [2][3][14]. Group 1: Collaboration with Eisai - Two years ago, BlissBio signed a collaboration agreement with Eisai for BB-1701, which included potential milestone payments and revenue sharing, with a total value of up to $20 billion [5][6]. - In April 2023, a strategic clinical trial collaboration was established, allowing Eisai to retain rights for global development outside of Greater China [5][6]. - The collaboration has been pivotal for BlissBio, as Eisai was not only a major client but also a significant shareholder, contributing to the company's financial backing [13][14]. Group 2: Clinical Trial Data and Termination of Collaboration - Recent clinical trial data revealed that Eisai's trial showed an objective response rate (ORR) of only 14.3%, while BlissBio's own trial reported an ORR of 21.4%, raising questions about the competitiveness of BB-1701 [14][15]. - The termination of the collaboration was formalized in May 2025, with Eisai opting not to exercise its strategic rights, which significantly diminishes BlissBio's revenue prospects [14][15]. - The loss of Eisai as a client is expected to severely impact BlissBio's financial situation, with projected revenue from Eisai dropping by 87.65% in 2024 [16]. Group 3: Financial Implications - BlissBio's revenue is projected to plummet from 180 million yuan in 2023 to 22.59 million yuan in 2024, primarily due to the loss of Eisai's contributions [16]. - The company's gross profit is expected to shrink dramatically, leading to a net loss that could expand from 207 million yuan to 557 million yuan [16]. - High R&D expenditures and significant liabilities from investor agreements are contributing to BlissBio's financial distress, with total liabilities reaching 1.76 billion yuan by the end of 2024 [16].

Core Viewpoint - The rapid development of the global innovative drug industry has led to a significant opportunity for the CDMO (Contract Development and Manufacturing Organization) sector, with Shanghai Haoyuan Pharmaceutical Co., Ltd. positioning itself as a leader in the ADC (Antibody-Drug Conjugate) niche [1][2]. Group 1: Company Strategy and Market Position - Haoyuan Pharmaceutical has identified ADC as a key area for growth, establishing core competencies and positioning itself in the first tier of CDMO providers in this field [1][2]. - The company has successfully undertaken over 110 ADC projects in 2024, with 12 small molecule products related to ADC having completed FDA filings [2]. - The company reported a revenue of 2.254 billion yuan in 2024, a year-on-year increase of 20.62%, and a net profit of 202 million yuan, up 58.17% year-on-year [2]. Group 2: Technological Advancements - ADC technology, which combines antibodies, linkers, and cytotoxic drugs, allows for targeted cancer treatment, minimizing damage to normal tissues [2]. - Haoyuan Pharmaceutical has developed proprietary technologies in ADC, having been a pioneer in this field since its establishment in 2006 [3]. - The company has collaborated with AI pharmaceutical firms to enhance drug development processes, establishing an AI Drug Exploration Joint Laboratory with East China Normal University [3]. Group 3: International Expansion - The company is actively expanding its international market presence, having serviced numerous ADC "outbound" orders, with nine overseas licensing transactions reported in the first half of the year [4]. - Haoyuan Pharmaceutical has established a CDMO base in Chongqing, which is the largest of its kind in Southwest China, and has passed EU quality audits to facilitate international market expansion [4][5]. - The company has set up business warehousing centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions globally [5]. Group 4: Future Prospects - Haoyuan Pharmaceutical is not only focusing on ADC but is also exploring emerging fields such as PDC (Peptide-Drug Conjugates), RDC (Radioisotope-Drug Conjugates), and ApDC (Aptamer-Drug Conjugates) [5]. - The company aims to create a full-chain service model that integrates technology research, industrialization, and global service, thereby establishing competitive barriers [5].

Core Viewpoint - The company, InnoCare Pharma (9606.HK), is facing a dual crisis of significant losses and high debt levels, with a cumulative loss of 1.795 billion yuan by the end of 2024 and a single-year loss of 1.05 billion yuan in 2024, nearly doubling year-on-year [2][4]. Financial Performance - By the end of 2024, the total liabilities of the company surged to 4.112 billion yuan, with a debt-to-asset ratio reaching 196.7% and a short-term debt gap exceeding 2.763 billion yuan [4][9]. - The company's revenue is heavily reliant on the "License-out" model, which accounted for nearly 100% of its income in 2024, highlighting its vulnerability due to dependence on partner payments [2][12]. - The gross profit margin for 2024 dropped significantly by 35.64 percentage points to 40.42%, indicating a continuous decline in profitability [12][13]. Research and Development Challenges - The company's core product, DB-1303, faces competition in efficacy and uncertainty in commercialization, with its objective response rate (ORR) data being inferior to competitors [3][14]. - The second product, DB-1311, has no prior approval examples and its clinical data remains immature, posing high risks of research failure or delays [3][15]. - R&D expenditures have increased significantly, with 2024's R&D spending reaching 837 million yuan, contributing to the substantial losses [7][8]. Revenue Structure - The primary revenue source for the company is from licensing agreements, with a notable partnership with BioNTech yielding a $170 million upfront payment for two drugs [13]. - In 2024, the License-out revenue reached 1.937 billion yuan, reflecting an 8.3% year-on-year increase, while other product revenues were negligible [12][13]. Debt and Cash Flow Issues - The company's current liabilities amount to 3.872 billion yuan, constituting 94.2% of total liabilities, while cash on hand is only 1.209 billion yuan, leading to a short-term debt gap of 2.763 billion yuan [9]. - The net increase in cash and cash equivalents for 2024 was only 78 million yuan, the lowest in three years, insufficient to cover even one month of laboratory R&D expenses [9].

Group 1: Financial Performance - In 2024, the company achieved a revenue of 645.02 million yuan, representing a year-on-year growth of 18.65% [1] - The net profit attributable to shareholders for 2024 was 123.83 million yuan [1] - In Q1 2025, the company reported a revenue of 186.49 million yuan, with a year-on-year increase of 27.73% [1] - The net profit attributable to shareholders in Q1 2025 was 40.58 million yuan, reflecting a growth of 32.30% [1] Group 2: Strategic Focus and Market Position - The company is concentrating on biopharmaceuticals and cell immunotherapy, driving core business development and global strategy [1] - There is a continuous increase in demand for biological reagents such as recombinant proteins, driven by the recovery of the innovative drug market [2] - The company aims to enhance its leadership and competitive advantage in the industry through improved technology and product development [2] Group 3: Product Development in CGT and ADC - The company provides comprehensive solutions for cell and gene therapy (CGT), addressing challenges in R&D technology, product quality, and supply chain stability [3] - Over 50 high-quality GMP-grade products have been developed, including cytokines and antibodies for CGT applications [5] - In the ADC field, the company focuses on five core elements: suitable antigen targets, highly specific antibodies, effective toxin molecules, quality linkers, and precise Drug Antibody Ratio (DAR) [6][7]

Company Overview - BlissBio Inc. (百力司康) submitted its prospectus for listing on the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and Jianyin International as joint sponsors [1] - The company was founded on December 7, 2017, by Wei Ziping and Zhou Yuhong, and operates under the name BlissBio Biopharmaceutical (Hangzhou) Co., Ltd. [3] Financial Information - The registered capital of BlissBio Biopharmaceutical (Hangzhou) Co., Ltd. is RMB 1.931661 million, down from RMB 2.814294 million due to a recent capital reduction [3][4] - The company has undergone five rounds of domestic financing from 2018 to 2023, raising RMB 35 million in the angel round, RMB 110 million in the A round, RMB 435 million in the B round, RMB 123.8 million in the B+ round, and RMB 170 million in the B++ round [5][6] Shareholding Structure - As of now, Wei Ziping holds 15.71% of the shares, Zhou Yuhong holds 10.48%, and they collectively hold 8.01% through PartnerBio Corporation [6] - Other significant shareholders include Hillhouse Capital, which holds 11.70%, and Dongfang Fuhai with 11.55% [8] Product Pipeline - BlissBio is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address unmet needs in cancer treatment [8] - The core product, BB-1701, is an HER2-targeted ADC candidate primarily aimed at breast cancer and non-small cell lung cancer [8][9] - The company has three additional ADC candidates in clinical stages: BB-1705 (EGFR ADC), BB-1712 (anti-B7-H3 ADC), and BB-1709 (CD73 ADC) [9] Revenue and Losses - BlissBio reported revenues of approximately RMB 180.2 million in 2023, which is expected to drop by 87.5% to about RMB 22.6 million in 2024, primarily due to a one-time milestone payment in 2023 [10] - The net losses for 2023 and 2024 are projected to be approximately RMB 206.4 million and RMB 556.6 million, respectively, totaling around RMB 760 million [11]

Core Viewpoint - BlissBio Inc. is advancing its lead candidate BB-1701, a HER2-targeted ADC, aimed at addressing unmet needs in cancer treatment, particularly for patients with HER2-positive breast cancer and other HER2-expressing cancers [1][2][4]. Company Overview - Founded in 2017, BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) [1][2]. - The company has submitted its IPO prospectus to the Hong Kong Stock Exchange, with plans for a main board listing [1]. Product Pipeline - BlissBio's ADC pipeline includes four clinical-stage candidates: - BB-1701 (HER2-targeted ADC for breast cancer and other cancers) - BB-1705 (EGFR-targeted ADC) - BB-1712 (anti-B7-H3 ADC) - BB-1709 (CD73 ADC) - All pipeline assets have full global rights [2][4]. BB-1701 Details - BB-1701 is the leading clinical candidate for treating patients previously treated with TOP1-i ADCs, utilizing the established drug Ailubulin as its payload [4]. - The drug has shown promising efficacy and manageable safety in ongoing Phase II studies across the US, Europe, Japan, and China [4]. - The company is actively exploring the expansion of BB-1701's indications and potential combinations with other therapies, such as immunotherapy and targeted treatments [4]. Funding and Use of Proceeds - BlissBio has secured investments from notable institutions, including Hillhouse Capital and Cormorant Asset Management [5]. - The funds raised from the IPO will primarily support the development and commercialization of BB-1701, as well as other key products and pipeline assets [5].

Core Viewpoint - BlissBio Inc. (百力司康) has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and Jianyin International acting as joint sponsors [1] Company Overview - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address significant unmet needs in cancer treatment. The company has a pipeline consisting of four clinical-stage ADC candidates [4] - The core product, BB-1701, is a HER2-targeted ADC candidate primarily aimed at breast cancer (BC), non-small cell lung cancer (NSCLC), and potentially other HER2-expressing cancers. The company also has three other ADC candidates in clinical stages: BB-1705 (EGFR ADC), BB-1712 (anti-B7-H3 ADC), and BB-1709 (CD73 ADC) [4] Product Development - BB-1701 is the leading HER2 ADC candidate for patients previously treated with TOP1-i ADC globally. It utilizes Ailubulin as an effective payload, leveraging its multifaceted mechanism of action and differentiated resistance mechanisms. The drug has shown promising efficacy and manageable safety in ongoing Phase II studies in the US, Europe, Japan, and China, with only three cases of ILD reported among 260 patients [5] Manufacturing and Quality Control - The company possesses essential capabilities in chemistry, manufacturing, and control (CMC) development, providing high-quality, efficient, and cost-effective solutions for antibody development and ADC construction. The company has demonstrated the ability to advance projects from preclinical candidates to Investigational New Drug (IND) status in 14 months, significantly faster than the industry average of 18 months [6] Financial Performance - For the fiscal years 2023 and 2024, BlissBio Inc. reported revenues of approximately 180.2 million RMB and 22.6 million RMB, respectively. The company incurred losses of approximately 206.4 million RMB in 2023 and 556.6 million RMB in 2024 [6][7]

Group 1 - As of June 20, 2025, there have been 32 new listings in the Hong Kong stock market, raising a total net amount of HKD 77.969 billion, significantly higher than the total of HKD 13.464 billion raised in the first half of 2024 [1] - The number of A-share companies listing in Hong Kong has increased, with 6 A+H share companies successfully listing this year, reflecting strong demand from investors for quality A-share listings [1] - The 6 A+H share companies had a strong debut in the Hong Kong market, with most experiencing double-digit percentage increases, and Chifeng Jilong Gold Mining Co. seeing a cumulative increase of 117.20% [1] Group 2 - The A-share company Sanhua Intelligent Controls is set to list in Hong Kong on June 23, 2025, with an issue price of HKD 22.53, aiming to raise HKD 0.811 billion for product development and global expansion [2] Group 3 - Traditional consumer stocks have underperformed, while new consumption stocks have thrived, with companies like Haitian Flavoring and Food Co. and Shubao International seeing significant stock price increases [3] - New consumption stocks such as milk tea brands have shown remarkable performance, with shares of Misha Group and Hu Shang Ayi increasing by 153.83% and 20.67% respectively since their listings [3] Group 4 - The trend of collectible toy stocks has also emerged, with Pop Mart International seeing a cumulative stock price increase of over 100% [4] - The toy company Blok has attracted significant interest, with its Hong Kong public offering being oversubscribed by 6,000 times [4] Group 5 - Five unprofitable biotech companies have listed in Hong Kong this year, with Mirxes and Brainstorm Aurora showing strong stock performance since their listings, with increases of 48.71% and 113.66% respectively [5][6] - The focus on "hard tech + medical" sectors has led to high valuations for these unprofitable biotech firms, despite their current losses [6] Group 6 - At least 10 more companies are expected to list in the remaining days of June, including traditional consumer stocks and unprofitable biotech firms, with their performance yet to be determined [7][8]

Group 1 - The core agreement involves a strategic collaboration between Xiansheng Pharmaceutical's subsidiary Xiansheng Zaiming and US biopharmaceutical company NextCure for the development and commercialization of the antibody-drug conjugate (ADC) SIM0505, targeting CDH6, with a total potential payment of up to $745 million [2][5] - SIM0505 is positioned as a novel ADC with a proprietary TOPO inhibitor payload, showing strong anti-tumor effects in preclinical studies and a high systemic clearance rate, indicating potential for an expanded therapeutic window [3][4] - The collaboration includes a unique bidirectional technology partnership, allowing NextCure to utilize Xiansheng Zaiming's proprietary ADC linker and TOPO inhibitor payload for its own ADC development, while Xiansheng Zaiming retains rights for this new ADC in Greater China [4] Group 2 - The $745 million deal marks a significant milestone in Xiansheng Pharmaceutical's strategy for international expansion and highlights the successful global outreach of Chinese innovative drugs through business development (BD) models [5] - The collaboration underscores the international recognition of Chinese pharmaceutical companies' capabilities in cutting-edge technologies like ADCs, with Xiansheng Zaiming's proprietary payload being noted for its potential superior safety and efficacy compared to other topoisomerase inhibitors [5][6] - In recent years, Xiansheng Pharmaceutical has secured over $2.3 billion in potential transaction value through three overseas licensing agreements for self-developed innovative drugs, indicating a proactive shift towards globalizing Chinese original drugs [5]